ArticleDiscover oncology2026
Immune-related gene signature for predicting biochemical recurrence after RP in prostate cancer subtypes.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic role of molecular subtypes of prostate cancer (PCa) patients is still unclear. And we speculated whether the change of immunologic and hallmark gene sets of adjacent notumor tissues could promote the BCR of PCa patients.
methodsWe intended to identify PCa subtypes and find significant gene sets based on the activity changes of immunologic and hallmark gene sets in tumor and nontumor tissues to predict biochemical recurrence (BCR)-free survival. In addition, cell-based assays were utilized to validate the function of the gene in PCa.
resultsWe calculated and analyzed these gene sets related to BCR in tumor and notumor tissues through gene set variation analysis (GSVA) and then found three clinically relevant subtypes of PCa by nonnegative matrix factorization method (NMF) in immunologic and hallmark gene sets. Patients with subtype 2 had better BCR-free survival than other subtypes. Using the least absolute shrinkage and selection operator method (LASSO), two prognostic gene sets in tumor but not in notumor tissue were identified frequently. Functional enrichment analysis revealed that genes from these two significant gene sets closely correlated with cell cycle in tumor tissue. Then, we applied random forest (RF) and artificial neural network (ANN), to identify gene In review biomarkers in predicting BCR and we found 36 genes related to the high risk of BCR. CENPE is the only common gene and can be used as a prognostic gene of BCR. Cell-based assays validated that CENPF promoted tumor proliferation in PCa.
conclusionThree clinically relevant subtypes of PCa were identified. Two significant genes sets were related to the cell cycle and ATPase activity. And CENPF promotes tumor proliferation as an oncogene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.